Aelis Farma (FRA:69O) Selling, General, & Admin. Expense: €1.22 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:69O Aelis Farma SA FRA:69O
28 GF Score
Price €1.00
GF Value €0.94
! 4 Warning Signs
View Full Analysis

What is Aelis Farma Selling, General, & Admin. Expense?

Aelis Farma FRA:69O -0.20% 28 Selling, General, & Admin. Expense is €1.22 Mil as of Dec. 2025. GuruFocus rates FRA:69O with a GF Score™ of 28/100 and a GF Value™ of €0.94. The stock has 4 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Aelis Farma's selling, general, & admin. expense for the six months ended in Dec. 2025 was €0.54 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was €1.22 Mil.


Aelis Farma  (FRA:69O) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Aelis Farma Selling, General, & Admin. Expense Related Terms


Aelis Farma Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Aelis Farma's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aelis Farma Selling, General, & Admin. Expense Chart

Aelis Farma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only 0.56 1.67 1.10 1.30 1.22

Aelis Farma Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.64 0.67 0.68 0.54

FRA:69O vs VRTX, REGN, RVMD: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Aelis Farma's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aelis Farma Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aelis Farma's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Aelis Farma's Selling, General, & Admin. Expense falls into.


FRA:69O
28GF Score
Aelis Farma SA FRA:69O
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aelis Farma Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of €1.22 Mil mean?
Aelis Farma (FRA:69O) has a Selling, General, & Admin. Expense of €1.22 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Aelis Farma and its competitors.
Is Aelis Farma's Selling, General, & Admin. Expense too high?
Aelis Farma's current Selling, General, & Admin. Expense is €1.22 Mil. Overall, Aelis Farma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Aelis Farma's Selling, General, & Admin. Expense compare to VRTX and REGN?
Aelis Farma's Selling, General, & Admin. Expense of €1.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Aelis Farma and its competitors. Aelis Farma's current Selling, General, & Admin. Expense is €1.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aelis Farma stock overvalued right now?
Aelis Farma (FRA:69O) has a current Selling, General, & Admin. Expense of €1.22 Mil. The stock's GF Value™ is €0.94, compared to a current price of €1.00 — trading 6.4% above its estimated fair value. The current Selling, General, & Admin. Expense is €1.22 Mil. Aelis Farma's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Aelis Farma (FRA:69O), the current Selling, General, & Admin. Expense is €1.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aelis Farma (FRA:69O) Overvalued in 2026?

Based on GuruFocus' analysis, Aelis Farma stock appears to be overvalued. The current stock price of €1.00 is trading 6.4% above its estimated GF Value™ of €0.94.

Key valuation signals for FRA:69O:

  • Selling, General, & Admin. Expense: €1.22 Mil
  • GF Value™: €0.94 vs. price of €1.00 (6.4% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the FRA:69O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aelis Farma Business Description

Other Exchanges AELIS:France
Address 2 rue Robert Escarpit, IECB, Pessac, Bordeaux, FRA, 33607
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases. The Company operates in only one business segment: the research and development of pharmaceutical products.
28GF Score

Get the complete analysis for FRA:69O

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.00
Price
€0.94
GF Value